Author

S. Gruber

h-index 12 View on Semantic Scholar

We have 2 of 70 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-world clinical outcomes among patients with EGFR-mutated (Ex19del/L858R) metastatic NSCLC treated at City of Hope with osimertinib monotherapy by TP53 alteration status.

703 Background: Epidermal growth factor receptor mutations (EGFRm) occur in ~15% of non-small cell lung cancer (NSCLC) cases, with exon 19 deletions (Ex19del) and exon 21 L858R substitutions (L858R) comprising 85-90%. Osimertinib (Osi) monotherapy (mono) is one of the first-line (1L) treatment options, while mo...

S. Gruber, P. Vadagam, L. Morrison et al. · JCO Oncology Practice · 0 citations

Open access Jul 2026

Familial Risk Stratification Across Cancer Syndromes Using Fam3PRO

Fam3PRO provides a validated approach for familial risk stratification across a broad spectrum of cancer types, including estimates of carrier probabilities and future cancer risk, and is validated on three independent multi-ethnic panel cohorts.

Jane W. Liang, Gregory E. Idos, C. Hong et al. · Genetics in Medicine · 0 citations